Comparison of IDH and ATRX by immunohistochemistry with 1p/19q co-deletion by FISH in Oligodendrogliomas

Zahoor   Hussain; Syed Salman Ali; Sumaira Ilyas; Qurat Ul Ain Mati; Sidra Shoukat; Sawera Ilyas

doi:10.51253/pafmj.v76iSUPPL-7.12321

Authors

Zahoor Hussain Department of Histopathology, Combined Military Hospital Lahore/National University of Medical Sciences (NUMS) Pakistan
Syed Salman Ali Department of Histopathology, Combined Military Hospital Lahore/National University of Medical Sciences (NUMS) Pakistan
Sumaira Ilyas Department of Haematology, Combined Military Hospital Lahore/National University of Medical Sciences (NUMS) Pakistan
Qurat Ul Ain Mati Department of Histopathology, Combined Military Hospital Lahore/National University of Medical Sciences (NUMS) Pakistan
Sidra Shoukat Department of Histopathology, Combined Military Hospital Lahore/National University of Medical Sciences (NUMS) Pakistan
Sawera Ilyas Army Medical College/National University of Medical Sciences (NUMS), Rawalpindi Pakistan

DOI:

https://doi.org/10.51253/pafmj.v76iSUPPL-7.12321

Keywords:

ATRX, IDH, Oligodendrogliomas, 1p/19q co-deletion

Abstract

Objective: To determine 1p/19q co-deletion by Fluorescence in situ hybridization (FISH) based on positive expression of IDH and ATRX by immunohistochemistry (IHC) in oligodendrogliomas.

Study Design: Cross-sectional study.

Place and Duration of Study: Department of Histopathology, Armed Forces Institute of Pathology, Rawalpindi Pakistan, from Oct 2021 to Jun 2022.

Methodology: A total of 58 cases of oligodendrogliomas having positive expression of IDH and ATRX were subjected to FISH for 1p/19q co-deletion. FISH results were correlated with clinicopathological parameters and IHC by using computer software SPSS version 23.

Results: In this study, age range is from 14 to 79 years, with mean of 40 years. 30(52%) cases are <40 years of age and 28(48%) cases are ≥40 years of age. There are 33(57%) males and 25(43%) females with a male to female ratio of 1.3:1. At the time of presentation, 25(43%) patients had headache, 19(33%) had focal neurological deficit, and 14(24%) had seizures. 1p/19q co-deletion by FISH was positive in 51(88%) specimens, whereas it was negative in 7(12%) specimens. 1p/19q co-deletion was not significantly associated with age, gender and clinical symptoms (p-value >0.05). Sensitivity & diagnostic accuracy of IHC with FISH as gold standard showed that combined sensitivity of IDH and ATRX was 100% with diagnostic accuracy of 87.93% for oligodendrogliomas.

Conclusion: It’s concluded that oligodendrogliomas can be diagnosed with combined positive expression of IDH and ATRX with sensitivity of 100% and diagnostic accuracy of 87.93% where FISH for 1p/19q co-deletion is not available.

Downloads

Download data is not yet available.

References

REFERENCES

1. Brat DJ, Aldape K, Colman H, Figrarella-Branger D, Fuller GN, Giannini C, et al. cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas. Acta Neuropathol 2020;139(3):603–608. http://doi.org/10.1007/s00401-020-02127-9

2. Sim J, Nam D-H, Kim Y, Lee I-H, Choi JW, Sa JK, et al. Comparison of 1p and 19q status of glioblastoma by whole exome sequencing, array-comparative genomic hybridization, and fluorescence in situ hybridization. Med Oncol 2018;35(5):60. http://doi.org/10.1007/s12032-018-1119-2

3. Huang J, Yu J, Tu L, Huang N, Li H, Luo Y. Isocitrate dehydrogenase mutations in glioma: From basic discovery to therapeutics development. Front Oncol 2019;9:506. http://doi.org/10.3389/fonc.2019.00506

4. Geevar T, Pai R, Chacko G, Malepathi K, Patel B, John J. Molecular profile of tumours with oligodendroglial morphology: Clinical relevance. Neurol India 2018;66(6):1726–1731. http://doi.org/10.4103/0028-3886.246275

5. Ammendola S, Caldonazzi N, Simbolo M, Piredda ML, Brunelli M, Poliani PL, et al. H3K27me3 immunostaining is diagnostic and prognostic in diffuse gliomas with oligodendroglial or mixed oligoastrocytic morphology. Virchows Arch 2021;479(5):987–996. http://doi.org/10.1007/s00428-021-03134-1

6. Kao PY, Ngo T, Zhang A, Chen JW, Manjunath BS. Brain tumor segmentation and tractographic feature extraction from structural MR images for overall survival prediction. International MICCAI Brain lesion Workshop. 2018;16:128–141. http://doi.org/10.1007/978-3-030-11726-9_12

7. Zachariah MA, Oliveira-Costa JP, Carter BS, Stott SL, Nahed BV. Blood-based biomarkers for the diagnosis and monitoring of gliomas. Neuro Oncol 2018;20(9):1155–1161. http://dx.doi.org/10.1093/neuonc/noy074

8. Liu J, Zhang X, Yan X, Sun M, Fan Y, Huang Y. Significance of TERT and ATRX mutations in glioma. Oncol Lett 2018; http://dx.doi.org/10.3892/ol.2018.9634

9. Fan H-C, Chen C-M, Chi C-S, Tsai J-D, Chiang K-L, Chang Y-K, et al. Targeting telomerase and ATRX/DAXX inducing tumor senescence and apoptosis in the malignant glioma. Int J Mol Sci 2019;20(1):200. http://doi.org/10.3390/ijms20010200

10. Tesileanu CMS, Vallentgoed WR, Sanson M, Taal W, Clement PM, Wick W, et al. Non-IDH1-R132H IDH1/2 mutations are associated with increased DNA methylation and improved survival in astrocytomas, compared to IDH1-R132H mutations. Acta Neuropathol 2021;141(6):945–957. http://doi.org/10.1007/s00401-021-02291-6

11. Chatterjee D, Radotra BD, Kumar N, Vasishta RK, Gupta SK. IDH1, ATRX, and BRAFV600E mutation in astrocytic tumours and their significance in patient outcome in north Indian population. Surg Neurol Int 2018;9. http://doi.org/10.4103/sni.sni_284_17

12. Haase S, Garcia-Fabiani MB, Carney S, Altshuler D, Núñez FJ, Méndez FM, et al. Mutant ATRX: uncovering a new therapeutic target for glioma. Expert Opin Ther Targets 2018;22(7):599–613. http://doi.org/10.1080/14728222.2018.1487953

13. Javed R, Akhtar N, Hassan U, Azam M, Loya A, Hussain M. Idh-1, Atrx and 1p19q co-deletion in diffuse gliomas. Pak Armed Force Med J 2020;70(2):571–577. http://doi.org/10.51253/pafmj.v70i2.4235.

14. Hu W-M, Wang F, Xi S-Y, Zhang X, Lai J-P, Wu H-Y, et al. Practice of the new integrated molecular diagnostics in gliomas: Experiences and new findings in a single Chinese center. J Cancer 2020;11(6):1371–1382. http://doi.org/10.7150/jca.38603

15. Mukherjee J, Johannessen TC, Ohba S, Chow TT, Jones L, Pandita A. Mutant IDH1 Cooperates with ATRX Loss to Drive the Alternative Lengthening of Telomere Phenotype in Glioma Mutant IDH1 Drives ALT and Gliomagenesis. Cancer res 2018;78:2966–2977. http://doi.org/10.1158/0008-5472.CAN-17-2269

16. Leeper HE, Caron AA, Decker PA, Jenkins RB, Lachance DH, Giannini C. IDH mutation, 1p19q codeletion and ATRX loss in WHO grade II gliomas. Oncotarget 2015;6(30):30295–305. http://doi.org/10.18632/oncotarget.4497

17. Reuss DE, Sahm F, Schrimpf D, Wiestler B, Capper D, Koelsche C, et al. ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an “integrated” diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma. Acta Neuropathol 2015;129(1):133–146. http://doi.org/10.1007/s00401-014-1370-3

18. Walach H. Omega. Karger Kompass Onkol 2020;7(3):176–176. http://dx.doi.org/10.1159/000510435

19. Tariq MU, Ahmed Z, Moatter T. Role of chromosomal 1p/19q co-deletion on the prognosis of oligodendrogliomas in Pakistan. Ann Oncol 2017;28(suppl_10):x38. http://doi.org/10.1093/annonc/mdx657.012

20. Laghari AA, Khalid MU, Qadeer N, Shamim MS. Prognostic value of 1p/19q chromosomal codeletion in patients with oligodendroglioma. J Pak Med Assoc 2019;69(1):132–134.

21. Rathore S, Iftikhar MA, Mourelatos Z. Prediction of overall survival and molecular markers in gliomas via analysis of digital pathology images using deep Learningarxiv 2019. http://doi.org/10.48550/arXiv.1909.09124